Neoadjuvant REGN2810 (Cemiplimab) in Cutaneous Basal Cell Carcinoma of the Head and Neck

Disease Sites:

Head/Neck

Staging:

Phase II

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Cemiplimab

Principal Investigator(s):

Topf, Michael

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

08-15-2025

Trial Type:

Treatment

Protocol ID:

VICC-ITHAN23127

National Clinical Trial ID:

NCT05929664

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available